1Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea.

Tbe FDA approved retifanlimab-dlwr (Zynyz; Incyte), a PD-1-targeting mAb, in combination with chemotherapy for patients with inoperable or metastatic squamous cell carcinoma of the anal canal (SCAC).

Major Finding: Brain metastases that arise from various primary sites characteristically harbor chromosomal instability and an immunosuppressive stromal/immune composition.

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...

Researchers at the American Association for Cancer Research Annual Meeting 2025 demonstrated that a bridged proteolysis targeting chimera (PROTAC) could enable the inclusion of more ligases in the ...

1Department of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, ...

The FDA has approved belzutifan (Welireg; Merck) for patients with locally advanced, inoperable, or metastatic pheochromocytoma or paraganglioma (together known as PPGL), rare neuroendocrine tumors ...

The FDA granted accelerated approval to the antibody–drug conjugate (ADC) telisotuzumab vedotin (Emrelis; AbbVie), which targets the receptor tyrosine kinase c-Met, for patients with locally advanced ...

With the recent advancements in anti-tumor immunotherapy, novel treatments have emerged and progressed rapidly. Several strategies are now being employed to enhance the efficacy of natural killer (NK) ...

1Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.